Year Founded
2010
Ownership
Private
Therapeutic Areas
Infectious DiseasesGastroenterology
Stage
Phase 3
Modalities
Microbial-based therapeutics

Vedanta Biosciences General Information

Lead candidate VE303 in Phase 3 for prevention of recurrent C. difficile infection. Published positive Phase 2 results in JAMA showing >80% reduction in CDI recurrence vs placebo. VE202 in Phase 2 for ulcerative colitis.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

VE303
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Vedanta Biosciences's pipeline data

Book a demo

Key Partnerships

Janssen Research & Development

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Vedanta Biosciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Vedanta Biosciences's complete valuation and funding history, request access »

Vedanta Biosciences Investors

AXA IM Alts
Investor Type: Venture Capital
Holding: Minority
The AMR Action Fund
Investor Type: Venture Capital
Holding: Minority
Bill & Melinda Gates Foundation
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »